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sisters, was described in 1974, the disease is ancient, with 
mutant alleles that are several thousand years old (2). We 
know that the genetic locus whose dysfunction leads to 
sitosterolemia encodes two genes, ABCG5 and ABCG8, whose 
proteins function as obligate heterodimers (3, 4). ABCG5 
and ABCG8 (also known as sterolins) are expressed only in 
hepatocytes, gallbladder epithelium, and enterocytes, and 
are responsible for excretion of sterols, with xenosterols 
preferred over cholesterol. Arguably, the naming of the 
disease has led to a bias in appreciating the fact that stero-
lins keep a vast range of xenosterols, not just sitosterol, 
from accumulating in the body (5). A better name should 
be xenosterolemia to reflect appreciation of this biology. 
Although the spectrum of xenosterols our diets contain 
is extensive, we show a few sterol structures that highlight 
the differences between cholesterol and these xenoste-
rols (Fig. 1). In general, the major differences reside in 
the R tail of the sterol structure, with change in shape 
that will likely impact their organization in membranes 
(6–8).
While the importance of cholesterol trafficking is well-
recognized for its roles in the pathogenesis of endothelial 
dysfunction, foam-cell formation, and atherosclerosis, 
ensuring that xenosterols are kept out and why [an evolu-
tionary mechanism, conserved from fish to man (9)], has 
garnered less attention. The loss of function in humans, 
as well as in animal models, shows that accumulation of 
Abstract The elucidation of the molecular basis of the rare 
disease, sitosterolemia, has revolutionized our mechanistic 
understanding of how dietary sterols are excreted and how 
cholesterol is eliminated from the body. Two proteins, 
ABCG5 and ABCG8, encoded by the sitosterolemia locus, 
work as obligate dimers to pump sterols out of hepatocytes 
and enterocytes. ABCG5/ABCG8 are key in regulating whole- 
body sterol trafficking, by eliminating sterols via the biliary 
tree as well as the intestinal tract. Importantly, these trans-
porters keep xenosterols from accumulating in the body. 
The sitosterolemia locus has been genetically associated 
with lipid levels and downstream atherosclerotic disease, 
as well as formation of gallstones and the risk of gallbladder 
cancer. While polymorphic variants raise or lower the risks 
of these phenotypes, loss of function of this locus leads to 
more dramatic phenotypes, such as premature atherosclero-
sis, platelet dysfunction, and thrombocytopenia, and, per-
haps, increased endocrine disruption and liver dysfunction. 
Whether small amounts of xenosterol exposure over a life-
time cause pathology in normal humans with polymorphic 
variants at the sitosterolemia locus remains largely unex-
plored.  The purpose of this review will be to summarize 
the current state of knowledge, but also highlight key con-
ceptual and mechanistic issues that remain to be explored.—
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The description of the disease sitosterolemia by Bhat-
tacharyya and Connor initiated a fundamental rewrite of 
how dietary sterols traffic and are eliminated by the body 
(1). And while sitosterolemia, named after the most abun-
dant xenosterol detected in the plasma of the two affected 
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xenosterols leads to dramatic phenotypes, such as mac-
rothrombocytopenia and platelet dysfunction, liver disease, 
and cholesterol accumulation with xanthoma formation 
and atherosclerosis (10), and in mouse models (but not 
humans), infertility, immune dysfunction, and cardiomy-
opathy have been reported (11–13). This begs the question 
whether a lifetime of low level exposure to dietary bioactive 
xenosterols, whose levels of entry and retention may be al-
tered by polymorphisms in ABCG5 and ABCG8, may have 
biological consequences. This review will aim to highlight 
areas that, therefore, need further exploration.
GENETIC VARIATION AT THE SITOSTEROLEMIA 
LOCUS AND CLINICAL IMPLICATIONS
ABCG5 and ABCG8 were key suspects in regulating cho-
lesterol homeostasis in atherosclerotic CVD (ASCVD). This 
was supported by the clinical observations of severe, and 
sometimes fatal, atherosclerosis in humans with sitosterol-
emia (though see below). Support for this contention came 
from the genome-wide association studies, which showed a 
link not only between genetic variations at sitosterolemia 
locus (previously referred to as STSL) and lipid levels, but 
also for coronary artery disease (14–16). And not surpris-
ingly, because the ABCG5/ABCG8 heterodimer pumps 
cholesterol into bile (17–21), this locus was shown to pre-
dispose to gallstone disease (22–28). What is surprising, 
and the mechanistic connection remains to be addressed, 
was the link between a presumed hypermorphic variant, 
D19H, in ABCG8 and gallbladder cancer risk (25, 29). This 
locus is one of the strongest known genetic risk factors for 
this very rare cancer (though the genetic risk remains small). 
One pathway of how this may occur is that this variant leads 
to increased gall stone formation, subsequent inflamma-
tion, and consequently a predisposition to gallbladder can-
cer; this explanation remains unsubstantiated. Cancer, by 
its nature, requires multiple genetic changes to occur and 
how this would be caused or accelerated by the sitosterolemia 
locus remains to be explored. It is also not clear whether the 
variant alters the kinds of xenosterols that are concentrated 
in the bile leading to the formation of gallstones, pro-
longed inflammation, generation of genotoxic agents, and 
then oncogenesis.
Studies of these genetic variants have been association 
studies (30) and none have demonstrated a specific mech-
anistic pathway altered by these variants; we assume that 
cholesterol pumping into the bile or intestine would be 
altered. However, the liver has a predilection for excretion 
of xenosterols into bile (31), and the hypothesis that one of 
these dietary xenosterols is mechanistically involved has 
not been explored.
CLINICAL MANIFESTATIONS
The many clinical manifestations of sitosterolemia have 
been well-documented in a number of reviews (10, 32, 33). 
In summary, asymptomatic subjects (typically identified by 
cascade screening once a proband has been identified) can 
manifest no symptoms or signs to varying levels of affecta-
tions. There is no question whether affected individuals 
can have severe ASCVD, sometimes with fatal presentations 
(34–38), but with increased knowledge and case identifica-
tion, many affected subjects have now been identified, who 
in the untreated state, seem to have very little evidence of 
ASCVD. Two new studies have now highlighted this. In five 
subjects who were diagnosed after investigation of hy-
perlipidemia (ages 19–32 years), no clinical evidence of 
ASCVD was identified (39). More recently, and provocatively, 
cascade screening in the Hutterites (where all of the cases 
have the same mutations and share a similar lifestyle), many 
subjects were identified with no overt clinical manifestation 
of ASCVD or any blood dyscrasia (40). The latter study is 
also remarkable, as it may shed light on an old observation 
by Salen and his colleagues who reported that hepatic LDL-
receptor expression was increased, in contrast to the para-
doxical suppression of cholesterol biosynthesis enzymes 
(41, 42). We had shown that children with sitosterolemia 
can manifest very high levels of cholesterol and had previ-
ously been misdiagnosed as having pseudo-homozygous 
familial hypercholesterolemia (43, 44), yet it is not clear 
Fig. 1. Sterol structures of cholesterol as well as some xenosterols. The structure of cholesterol in two views viewed “en face” and from a 
side (top and bottom, respectively) is shown in the far right. The mesh indicates the overall surface-based shape of the sterol, based upon the 
carbons and hydrogens, and the 3-hydroxyl oxygen is shown in red in all molecules at the bottom left of each molecule for orientation. The 
“R” tail at the right end of each molecule shows the greatest difference between cholesterol and the xenosterols. Note in the bottom profile 
that stigmasterol (yellow) looks very similar to cholesterol (magenta), but in the top row profile shows the bulkiness of its R tail compared with 
cholesterol. Thus the packing of these sterols in a lipid bilayer will be affected by the differences in the R tail of each of these molecules.
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why they have such very high levels of plasma cholesterol, 
a manifest defect in hepatic clearance of LDL particles. 
Mymin et al. (40) reported a nonsignificant inverse asso-
ciation between age and plasma cholesterol; when subjects 
were grouped by pre- or postpuberty, both plasma choles-
terol and sitosterol levels were significantly higher in pre-
pubertal compared with postpubertal subjects. In one 
subject, in the absence of treatment, these sterol levels also 
fell progressively with time, though never normalized 
(40). This suggests that hepatic expression of lipoprotein 
receptors is dramatically altered by the progressive accu-
mulation of xenosterols, and this process is influenced by 
puberty.
Macrothrombocytopenia
Macrothrombocytopenia is another phenotype that has 
been observed in humans with sitosterolemia (45–47). Re-
markably, this phenotype can be the only manifestation of 
sitosterolemia. The first description of this entity, Mediter-
ranean macrothrombocytopenia, was reported in Australia 
(48), and we suspect it was a cohort of subjects who had si-
tosterolemia; all of these subjects have been lost to follow-
up to allow confirmation. However, Rees et al. (45) showed 
that not only were plant sterols elevated in their cohort in 
Europe, they also confirmed mutations at the sitosterol-
emia locus as causative, a finding that has been now re-
ported from many other sites around the world. This 
platelet phenotype is also observed in the murine models 
of sitosterolemia (46, 49, 50). Mutations seen in macro-
thrombocytopenia are also seen in sitosterolemia without 
the platelet phenotype, suggesting that these manifesta-
tions may be dependent upon the type of xenosterol expo-
sure. While there is no doubt that xenosterol accumulation 
leads to platelet dysfunction (50), biogenesis of the platelet 
is also abnormal. The mechanism of how xenosterolemia 
affects platelet biogenesis remains to be explored. Addi-
tionally, it is assumed that these effects are from sitosterol 
accumulation (the most abundant accumulating xenoste-
rol), but more bioactive less abundant xenosterols could 
be responsible. Other possibilities are bulk xenosterols 
altering raft membrane structures, or as a result of displacing 
cholesterol from key active sites (51).
Liver disease
Although the first case of liver failure associated with 
sitosterolemia (52) was regarded as an outlier or coincidence 
(and was only interesting as liver transplantation cured the 
sitosterolemia), a second case with a fatal outcome has now 
been reported. Bazerbachi et al. (53) reported a case of 
idiopathic cirrhosis, denied heart transplant from severe 
coronary artery disease, only to discover that the patient 
had sitosterolemia with the implication that both organ 
failures were caused by his one underlying condition. This 
raises the issues of the underlying mechanism for liver dys-
function and failure, and how many idiopathic cirrhosis 
cases are undiagnosed sitosterolemia. Mutational reviews 
of the two cases do not indicate any uniqueness when com-
pared with others with sitosterolemia, and accumulation 
of misfolded proteins in the ER, akin to 1-antitrypsin 
deficiency, seems less likely (53). The Finnish case was het-
erozygous for mutations in ABCG8 (W361X and E423D) 
(52), but the US case was homozygous for premature 
stop codon in ABCG5 (R446X) (53). If so, then the hy-
pothesis of toxic xenosterol accumulation is again raised. 
And if it is a toxic xenosterol species, it may be hard to 
detect as most sterol profiles have, to date, been limited to 
reporting sitosterol, campesterol, and stigmasterol. Other 
lesser known sterols are rarely reported. Expression of 
these mutants in vivo may be required to explore these 
possibilities.
Transintestinal cholesterol excretion in humans
Until recently, it was assumed that an elevation of plant 
sterols in the blood was diagnostic of sitosterolemia. Even 
in cases of liver dysfunction and failure, plant sterols re-
main low and the only clinical scenario where they are ele-
vated is during administration of total parenteral nutrition, 
which contains large amounts of plant sterols (54, 55). This 
has now been challenged by a report of a case of primary 
biliary cirrhosis (PBC), where plant sterols were dramati-
cally elevated (56). It should be noted that plant sterols are 
not normally elevated in PBC, thus this is a unique case. 
While the speculation was that the liver sterolin function 
was affected by this autoimmune process (56), it should be 
noted that ABCG5/ABCG8 should remain functionally ac-
tive in the intestine, and they are key to transintestinal cho-
lesterol excretion (TICE). Thus, TICE should have resulted 
in maintaining lower plant sterol levels [akin to the restora-
tion of intestinal sterolin function by transgenes in the 
Abcg8 knockout mice (12), or in liver-only knockouts 
(57)], but it did not. In PBC, the secretion of bile into the 
biliary tree is dramatically reduced and perhaps in this case 
there may have been very little bile secreted; this would 
mean that for TICE to be effective, loss of all bile in the 
intestine may also impair TICE. Groen and colleagues have 
shown that the phospholipid content, rather than bile salts, 
was a major regulator of TICE (58), opening the avenue 
for therapeutic use of dietary phospholipids in cholestatic 
diseases to improve lipids via TICE and ABCG5/ABCG8. 
And in passing, it should be noted that TICE should be 
TISE, because sterols are excreted and continue to bias in-
terpretation in a cholesterol-centric manner.
REGULATION OF ABCG5/G8
The secretion of cholesterol into bile is coupled to the 
secretion of phospholipids and bile acids that forms the 
mixed micelle acceptors for cholesterol within the aqueous 
lumen of the canaliculus. Mouse models of ABCG5/G8 de-
ficiency suggest that the complex accounts for 70–90% of 
biliary cholesterol secretion (17, 20, 21), and in mouse 
models with a gain or loss of function, there is an approxi-
mate gene dosage effect on biliary sterol excretion (17, 18, 
20, 59). Factors that increase or decrease the coupling of 
biliary cholesterol secretion to bile acids and phospholipids 
are likely to be ABCG5/G8 dependent and reflect changes 
in either ABCG5/G8 abundance or activity, although it 
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should be noted that ABCG5/G8-independent biliary cho-
lesterol secretion has been reported (60, 61).
Transcriptional regulation of ABCG5/G8
Expression of sterolins is restricted to the liver, small in-
testine, and gallbladder epithelium, but the mechanisms 
responsible for this limited tissue distribution have not 
been elucidated (3, 62, 63). Within these tissues, ABCG5 
and ABCG8 are co-regulated at the transcriptional level, 
sharing a common bidirectional promoter of 374 base 
pairs that separates their initiation codons (3, 62, 64). Reg-
ulatory elements within the intergenic region have been 
identified for hepatocyte nuclear factor 4 (NR2A1), liver 
receptor homolog-1 (NR5A2), nuclear factor kappa-light-
chain-enhancer of activated B cells (NFB), and Forkhead 
box protein O1 (64–68). Liver X receptor (LXR) response 
elements have been mapped to two conserved regions 
roughly 100 kB distal to the intergenic promoter, shown to 
bind both LXR (NR1H3) and LXR (NR1H2) and syner-
gistically activate the ABCG5/G8 promoter in combination 
with retinoid X receptor  (NR2B1), GATA4, hepato-
cyte nuclear factor 4, and liver receptor homolog-1 (69). 
These findings corroborated earlier data in animal models 
demonstrating that ABCG5/G8 mRNAs were responsive to 
dietary cholesterol as well as LXR and retinoid X receptor 
agonists in a LXR- and LXR-dependent fashion (70). 
Farnesoid X receptor (FXR; NR1H4) receptor agonists 
have also been shown to regulate ABCG5/G8 mRNAs in 
cultured hepatocytes, suggesting a direct mechanism of 
action. However, FXR response elements have yet to be 
mapped for ABCG5/G8 (70, 71). Thus, while a number 
of transcriptional factors are implicated in regulating the 
sitosterolemia locus, there remains a paucity of direct evi-
dence of their roles.
In vivo, sterolin mRNAs and proteins can be modulated 
by a number of experimental conditions. Disruptions of 
bile acid metabolism alter hepatic ABCG5/G8 expression, 
presumably due to changes in bile acid signaling through 
FXR (72–74). Similarly, intestinal expression of ABCG5/
G8 is modulated by bile acids (75, 76). Tissue-specific dele-
tion of hepatic insulin receptors revealed a role for insu-
lin signaling in the regulation of ABCG5/G8 through 
Forkhead box protein O1 (67). Alterations in ABCG5/G8 
mRNAs have also been observed in experimental models 
of type 1 and type 2 diabetes, as well as in human diabetic 
subjects (77–81). Additional factors shown to alter hepatic, 
intestinal, or gallbladder ABCG5/G8 expression include 
thyroid hormone signaling, dietary calcium, iron depletion, 
constitutive androstane receptor agonists, and gallbladder 
disease (82–86). However, the molecular mechanisms un-
derlying these effects are unclear and the extent to which 
they reflect novel regulatory nodes for ABCG5/G8 or are 
secondary to disruptions in established regulators is not 
known.
CpG islands have been identified near the transcrip-
tional start sites for ABCG5 and ABCG8 and were hypo-
methylated in the liver and hypermethylated in kidney and 
cerebrum (87). This same study revealed differential his-
tone H3 acetylation between liver and these non-ABCG5/
G8-expressing tissues, suggesting that epigenetic mech-
anisms may control tissue-specific expression of the 
complex. A highly intriguing mechanism by which p53 
promotes gene expression is by recognition of a structural-
specific motif called triplex DNA (88). The ABCG5 proximal 
promoter contains a predicted T·A·T triplex. Expression of 
ABCG5 mRNA increased following transient transfection 
of p53 in cultured cells, as well as treatment with p53-stabi-
lizing agents in p53-positive cells, but not in p53-negative 
cells (88). However, expression of ABCG8 was not exam-
ined, the cultured cells were not of hepatic, intestinal, or 
gallbladder epithelial origin, and the extent to which this 
mechanism influences ABCG5/G8 expression or sterol 
metabolism is not known. Interestingly, the insulin recep-
tor was also identified as a T·A·T triplex-responsive gene. 
Whether this is coincidental or mechanistically links altera-
tions in insulin signaling and ABCG5/G8 expression is 
unclear.
Regulation of complex formation and trafficking
ABCG5 and ABCG8 are required to form a functional 
sterol transport complex. This marriage is formed as the 
complex folds in the ER and is dependent on the presence 
of N-linked glycans and the calnexin/calreticulin chaper-
one system (89). Using a series of chimeras comprised of 
the N- and C-terminal domains of ABCG1, ABCG2, ABCG5, 
and ABCG8, evidence for a an ER-retrieval signal within 
the N-terminal cytosolic domains of ABCG5 and ABCG8 
that prevents the monomers from exiting the ER prema-
turely was identified (90). The heterodimer complex for-
mation has now been supported by a high-resolution crystal 
structure (91) that will allow for future structure-function 
studies to be conducted (Fig. 2, graciously provided by 
Dr. Jyh-Yeung Lee, University of Ottawa). Although the 
N-terminal structures of ABCG5 and ABCG8 could not be 
established within the crystal structure (91), many of the 
nonsynonymous polymorphic changes, as well as the mis-
sense mutations can be mapped onto a structure (Fig. 2). 
The missense mutations (R419 and R550 in ABCG5 and 
L572, G574, L596, R573, L501, and L405 in ABCG8) are 
very close to the putative sterol-binding pocket [see also 
the putative sterol-binding pocket for a model of ABCG4 
(92) based upon the ABCG5/ABCG8 crystal structure]. In-
terestingly, the polymorphic residues, I523 in ABCG5 and 
G575 in ABCG8, would also be close to this site and form 
good future candidates to explore their effect on sterol-
specificity of binding. In polarized cultured hepatocytes, 
recombinant ABCG5/G8 was shown to reside at the cana-
licular membrane (93). Within the small intestine, endog-
enous mouse, as well as a human, ABCG8 transgenes were 
localized almost exclusively to the apical surface (19). How-
ever, biochemical fractionation and immunolocalization 
approaches suggest a broader intracellular distribution of 
ABCG5 and ABCG8 (94). More recently, a recombinant 
fluorescently tagged ABCG5/G8 complex was shown to re-
side in an intracellular pool that is recruited to the cana-
licular surface in response to a lithogenic diet (95). In 
isolated rat liver canalicular membranes, ABCG5 was shown 
to reside in Triton-soluble Lubrol-resistant microdomains 
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(96). Similar results were obtained using bile acids as 
detergents in which ABCG5, ABCB4, and ABCB11 are co-
localized, suggesting the complete biliary lipid secretion 
apparatus resides within microdomains at the canalicular 
surface (97).
Regulation of ABCG5/G8 activity
The mechanism by which ABCG5/G8 promotes (chole)
sterol efflux is not fully understood. It was originally sug-
gested that ABCG5/G8 function as a floppase, promoting 
the movement of cholesterol to the exofacial leaflet of the 
canalicular membrane based on the observation that there 
was less cholesterol in isolated canalicular membranes of 
ABCG8-deficient mice (98). In cell-based models, coex-
pression of ABCG5 and ABCG8 will promote cholesterol 
efflux to bile-acid micelles, but not other traditional accep-
tors, such as ApoAI, HDL, or cyclodextrins, indicating that 
the molecular mechanism by which ABCG5/G8 promotes 
sterol efflux at the apical membrane is distinct from other 
cholesterol efflux pumps, such as ABCA1 and ABCG1 
(99, 100). Using purified native mouse ABCG5/G8, sterol 
transport between donor and acceptor liposomes suggests 
a 1:1 stoichiometry for ATP hydrolysis and cholesterol 
transport, and bile acids could stimulate this ATP hydroly-
sis (101). Among the tested bile acids, cholate was the most 
potent at stimulating ATPase activity, whereas its taurine or 
glycine conjugates were approximately 50% less effective. 
Using various lipid extracts and defined preparations, the 
presence of cholesterol stimulated ATPase activity to vary-
ing degrees. Thus, the presence of both bile acids and cho-
lesterol appear to act cooperatively to activate the pump 
and promote cholesterol secretion. This is an attractive 
model for the coupling of bile acid and cholesterol secre-
tion and supported by the publication of the ABCG5 and 
ABCG8 crystal structures that show a sterol-binding pocket, 
which may undergo structural changes upon ATP bind-
ing to make this more available at the luminal surface 
for phospholipid:bile acid acceptors to allow for excretion 
(91). What remains to be established is whether this mech-
anism is constantly active or is regulated by translocation of 
these heterodimers from an intracellular location to the 
apical surface. The crystal structure should also allow for 
exploration of how missense mutations disrupt function, as 
well as how the nonsynonymous polymorphic variants seen 
in humans may alter function.
Under a number of conditions, cholesterol and bile se-
cretion can be uncoupled, resulting in reduced cholesterol 
excretion or the supersaturation of bile (102). The extent 
to which these conditions are due to alterations in ABCG5/
G8 activity awaits further investigation.
MOUSE MODELS USED TO ELUCIDATE  
THE IMPACT OF STEROLINS IN PHYSIOLOGY  
AND DISEASE
The genes encoding ABCG5 and ABCG8 have been dis-
rupted, as well as overexpressed, in mice in order to per-
form detailed physiological studies of sterolin function. 
Mice lacking functional sterolins in both liver and intestine 
have been created by standard gene targeting of Abcg5 
(21), Abcg8 (20), or both Abcg5 and Abcg8 (17). Recently, 
mice were created with liver- and intestine-specific knock-
outs of Abcg5 and Abcg8 (57). The integration of the hu-
man ABCG5 and ABCG8 genes into the genome of mice 
resulted in mouse models with increased sterolin function 
in both liver and intestine (18) or liver only (103). In addi-
tion, adenoviral vectors have been employed in mice to 
increase or restore hepatic ABCG5 and ABCG8 function 
(19, 104, 105). These various mouse models have been em-
ployed to study the impact of ABCG5/G8 on sterol absorp-
tion and secretion, sitosterolemia, reverse cholesterol transport 
(RCT), TICE, metabolic disease, and atherosclerosis.
Xenosterol exclusion from the body
Like patients with sitosterolemia, mice lacking ABCG5/
G8 function are unable to preferentially excrete xenoste-
rols into bile or the intestinal lumen. When fed a diet that 
contains phytosterols, mice with homozygous disruption of 
Abcg5, Abcg8, or both Abcg5 and Abcg8 consistently devel-
oped sitosterolemia (12, 17, 20, 21, 46, 49, 72, 106). Plasma 
and tissue phytosterol levels in mice with intestinal- or liver-
specific knockout of Abcg5 and Abcg8 were significantly less 
than those of mice with whole-body ABCG5/G8 deficiency 
Fig. 2. Localization of nonsynonymous and missense 
amino acid changes on a model of ABCG5 (G5)-
ABCG8 (G8) heterodimer crystal structure. Although 
the structures of the N termini of ABCG5 and ABCG8 
could not be determined in the crystals subjected to 
X-ray diffraction, many of the known mutations and 
polymorphic variants could be mapped (91). This fig-
ure was kindly provided by Dr. Jyh-Yeung Lee, Univer-
sity of Ottawa.
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(57). The rescue of intestinal ABCG5/G8 function in 
Abcg8/ mice also significantly reduced, but did not nor-
malize, plasma phytosterol concentrations (12). It can be 
concluded that intestinal ABCG5/G8 excretes the majority 
of xenosterols back into the lumen, acting as a first-pass 
gate. Hepatic ABCG5/G8 then pumps into the bile those 
xenosterols that had evaded the intestinal checkpoint.
In the absence of ABCG5/G8 function, xenosterols can 
accumulate at high levels in mice causing several pathologi-
cal conditions. Infertility was observed in male and female 
Abcg5/ and Abcg8/ mice consuming a phytosterol-
rich chow diet, but when phytosterol accumulation in the 
body was blocked with a meat-based (xenosterol free) diet, 
or the sterol absorption inhibitor, ezetimibe, fertility was 
restored (11, 12, 107). Several studies have shown that 
mice lacking functional ABCG5/G8 developed macro-
thrombocytopenia, a disorder characterized by signifi-
cantly reduced platelet levels and increased platelet size. 
Abcg5/, Abcg8/, and Abcg5/,Abcg8/ mice also dis-
played hemolytic anemia, prolonged bleeding times, and 
decreased platelet activation and aggregation (11, 49, 50). 
The macrothrombocytopenia and abnormal bleeding was 
the result of phytosterol accumulation in platelet membranes 
resulting in dysfunctional platelets (50). Mice deficient in 
ABCG5 and/or ABCG8 also developed cardiomyopathy 
characterized by phytosterol accumulation, histiocytic infil-
tration, multifocal fibrosis, and tissue calcification (11, 13, 
49, 50). Interestingly, the development of cardiomyopathy 
is dependent both on the presence of high levels of xenos-
terols, as well as intact B and T cell function (13).
Cholesterol absorption
Action of ABCG5/G8 in the enterocytes is believed to 
reduce cholesterol absorption. Fractional cholesterol ab-
sorption (FCA) decreased and fecal neutral sterol excretion 
(FNSE) increased in transgenic mice with both intestine 
and liver (INTLIV-Tg) overexpression of human ABCG5/
G8 (18, 108, 109). In contrast, FCA and FNSE were similar 
for wild-type controls and transgenic mice with liver-specific 
overexpression of human ABCG5/G8 (103). Because both 
transgenic lines had increased biliary cholesterol secre-
tion, the difference in FCA and FNSE between the models 
could have been due to the human and mouse ABCG5/ 
G8 pumping greater amounts of biliary and dietary choles-
terol out of the enterocytes and back into the intestinal 
lumen of the INTLIV-Tg mice. However, when consider-
ing that the INTLIV-Tg mice versus the wild-type controls 
had 6- to 7-fold more cholesterol in bile, the absolute 
amount of cholesterol absorbed by the INTLIV-Tg mice 
versus the wild-type controls would have been significantly 
greater even with the 50% reduction in FCA. It is also pos-
sible that the increased FNSE was due to the bile of the 
INTLIV-Tg mice becoming supersaturated with choles-
terol, thus reducing luminal cholesterol bioavailability to 
the enterocytes.
If overexpression of ABCG5/G8 decreases FCA and in-
creases FNSE, then it would be anticipated that the absence 
of ABCG5/G8 would have the opposite effects. FNSE was 
reduced, but FCA, when measured using the fecal dual 
isotope or plasma dual isotope methods, was unchanged in 
chow-fed Abcg5/, Abcg8/, and Abcg5/,Abcg8/ 
mice (17, 21, 72, 110, 111). Cholesterol absorption, as as-
sessed by the movement of luminal-infused cholesterol 
into lymph, was found to be decreased in two studies using 
Abcg5/,Abcg8/ mice and increased in another study 
using Abcg8/ mice (112–114). Compared with wild-type 
controls, mice with intestinal-specific ABCG5/G8 defi-
ciency had no changes in FCA or FNSE (57). These studies 
indicate that the absence of intestinal ABCG5/G8 does not 
lead to increased cholesterol absorption and, consequently, 
the reduced FNSE observed in whole-body ABCG5/G8-de-
ficient mice could be driven by dramatically decreased bili-
ary cholesterol secretion. Because most of the above studies 
were conducted in mice fed a chow diet (low in fat and 
cholesterol, but high in phytosterols), it will be important 
to determine the impact of liver and/or intestinal ABCG5/
G8 deficiency on cholesterol absorption in mice consum-
ing a Western-type diet (WTD) with a higher fat and cho-
lesterol content. It will also be essential to assess whether 
cholesterol absorption in these models is affected by the 
inclusion in the diet of animal- or plant-derived fats that 
contain cholesterol and phytosterols, respectively.
Biliary cholesterol secretion
ABCG5/G8 are critical to the secretion of cholesterol 
into the bile. Abcg5/, Abcg8/, whole-body, and liver-
specific Abcg5/,Abcg8/ mice fed a chow diet displayed 
a 70–90% reduction in biliary cholesterol concentration or 
secretion (17, 20, 21, 57). In contrast, transgenic overex-
pression of human ABCG5/G8 in liver and intestine in-
creased biliary cholesterol concentrations by 5-fold and 
>7-fold in chow-fed male and female mice, respectively 
(18). Biliary cholesterol concentration and secretion by he-
patic overexpression of human ABCG5/G8 was unchanged 
on a chow diet, but was increased 1.5- to 2-fold on a high-
cholesterol diet (103). In the absence of the biliary phospho-
lipid transporter, Abcb4, biliary cholesterol concentration 
in mice was very low and was not increased by the hepatic 
expression of a human ABCG5/G8 transgene, indicating 
that biliary phospholipid secretion is required for ABCG5/
G8-mediated cholesterol secretion (108). In addition, stud-
ies in which wild-type or Abcg8/ mice were infused with 
hydrophilic and hydrophobic bile salts indicated that 
ABCG5/G8 drives biliary cholesterol secretion by flopping 
cholesterol from the inner to outer leaflet of the canalicu-
lar membrane (98). When fed a lithogenic diet, Abcg5/ 
and Abcg5/,Abcg8/ mice, compared with control 
C57BL/6J mice, had decreased incidence of gallstone de-
velopment (115).
Macrophage RCT
Macrophage RCT (mRCT) is an anti-atherogenic path-
way through which excess cholesterol is effluxed from 
plaque macrophages, transported on lipoproteins to the 
liver, secreted into bile, and excreted from the body. The 
primary method used to assess mRCT quantifies the move-
ment of 3H-cholesterol from intraperitoneally injected 
macrophage foam cells to feces over 48 h (116). C57BL/6J 
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mice with adenoviral-mediated overexpression of murine 
ABCG5/G8 (AdABCG5/G8) displayed increased fecal 
macrophage-derived 3H-neutral sterol (i.e., cholesterol), 
consistent with an increase in biliary cholesterol secretion. 
However, because the sum of 3H-neutral sterol and 3H-bile 
acid in feces was similar for AdABCG5/G8 and AdNull con-
trols, it was concluded that increased hepatic ABCG5/G8 
function alone does not impact macrophage-to-feces RCT. 
Studies in sterolin-deficient mice found that, in spite of sig-
nificant reductions in biliary cholesterol secretion, mice 
lacking ABCG5/G8 function had no deficits in mRCT 
(105, 117, 118). However, treatment with LXR agonist in-
creased 3H-neutral sterol excretion from wild-type mice, 
but not Abcg5/,Abcg8/ mice, leading to the conclu-
sion that stimulation of mRCT by LXR activation requires 
ABCG5/G8 (117).
TICE
TICE is the elimination of plasma cholesterol into the 
intestinal lumen by enterocytes. Several studies have indi-
cated that intestinal ABCG5/G8 play an important role in 
TICE. Cholesterol fluxes, measured with tracer techniques, 
showed that the contribution of TICE to fractional neutral 
sterol excretion (FNSE) was 25% in Abcg5+/+ mice, but 
15% in Abcg5/ mice (110). Blocking cholesterol absorp-
tion with ezetimibe in wild-type mice elevated FNSE by 3.8-
fold and TICE was responsible for 74% of this increase 
(111). Treatment of wild-type mice with the FXR agonist, 
PX20606, stimulated FNSE and TICE to a level similar to 
that observed with ezetimibe (119). In the absence of ABCG8, 
ezetimibe or PX20606 treatment blunted the increase in 
FNSE and TICE (111, 119). To gauge the importance of 
intestinal ABCG5/G8 in RCT, mice with intestinal-specific 
deficiency of ABCG5/G8 were injected with 3H-cholesterol 
and the levels of 3H-cholesterol in bile and feces were mea-
sured. In spite of similar biliary cholesterol and FCA, the 
intestinal-specific ABCG5/G8 knockouts compared with 
wild-type control mice had decreased fecal 3H-cholesterol 
excretion, likely due to a reduction in TICE (57). In con-
trast to the above studies, no difference in TICE was ob-
served when measured in wild-type or sterolin mice by 
intestinal perfusion (120). The overall results indicate that 
ABCG5/G8 play a major role in TICE.
Atherosclerosis
Atherosclerosis development has been assessed in trans-
genic mice with both intestine and liver (IntLiv-Tg) and liver 
only (Liv-Tg) expression of human ABCG5/G8. Compared 
with controls lacking only the LDL receptor (Ldlr/), 
IntLiv-Tg;Ldlr/ mice fed a WTD for 6 months had sig-
nificantly less aortic atherosclerosis (109). The combina-
tion of increased biliary cholesterol secretion and decreased 
cholesterol absorption in the IntLiv-Tg;Ldlr/ mice re-
sulted in a significant reduction in the plasma choles-
terol. In contrast, the Liv-Tg on either the LDLR or ApoE 
knockout background did not have reduced atherosclero-
sis development (103). Liv-Tg;ApoE/ mice fed chow and 
Liv-Tg;Ldlr/ mice fed WTD had significantly increased 
biliary cholesterol secretion, but compared with controls, 
no changes in cholesterol absorption or plasma cholesterol 
concentrations were noted. It was concluded that athero-
sclerosis was unaltered in IntLiv-Tg mice because the in-
creased biliary cholesterol was being absorbed back into 
the body. When fed a WTD plus the cholesterol absorption 
inhibitor, ezetimibe, Liv-Tg;Ldlr/ compared to Ldlr/ 
mice displayed significant reductions in total plasma cho-
lesterol and atherosclerosis development (121).
To assess the impact of ABCG5/G8 deficiency and con-
sequently increased phytosterol levels on atherosclerosis 
development, whole-body ABCG5/G8-deficient mice ex-
pressing or lacking LDL receptor were studied (109). Feed-
ing either a chow diet or WTD for 7 months caused a 
significant increase in plasma phytosterol concentration in 
Abcg5/,Abcg8/ and Abcg5/,Abcg8/;Ldlr/ mice 
compared with wild-type controls. Regardless of the geno-
type, atherosclerosis did not develop in mice fed chow. Con-
sumption of the WTD by the Abcg5/,Abcg8/;Ldlr/ 
and Abcg5+/+,Abcg8+/+;Ldlr/ mice resulted in similar in-
creases in total plasma sterols and atherosclerosis formation. 
Based upon these results, it was concluded that there was no 
association between phytosterol levels and atherosclerosis 
development in mice. The lack of difference in atheroscle-
rosis formation between the Abcg5/,Abcg8/;Ldlr/ 
and Abcg5+/+,Abcg8+/+;Ldlr/ could have been the result 
of LXR activation by phytosterols offsetting the decreased 
biliary cholesterol secretion (122).
Metabolic disease
ABCG5/G8 function also appears to limit the develop-
ment of metabolic disease. Sterolin-deficient mice fed a 
phytosterol-rich chow diet developed hypertriglyceridemia 
due to increases in intestinal triglyceride (TG) absorption 
and hepatic TG secretion and reductions in TG-rich lipo-
protein clearance and lipoprotein lipase activity (123). 
When fed a phytosterol-free high-fat diet, these mice had 
increased hepatic TG and cholesterol accumulation lead-
ing to liver inflammation, loss of glycemic control, and in-
sulin resistance (124). Obese db/db mice have reduced 
hepatic ABCG5/G8 protein and decreased biliary choles-
terol (80). Adenoviral-mediated overexpression of ABCG5/
G8 in db/db mice increased biliary cholesterol secretion 
and restored hepatic insulin sensitivity resulting in re-
duced fasting glucose and TGs and improved glucose tol-
erance (104). However, the relationship between biliary 
and intestinal sterol transport and the underlying mecha-
nisms that contribute to metabolic disturbances remain 
unclear.
CONCLUSIONS
The human diet is very varied and exposes us to more 
than 60 different xenosterols, from shellfish, mushrooms, 
yeasts, seaweeds, plants, etc., and we need to have robust 
mechanisms to prevent toxic xenosterols from accumula-
tion. The sitosterolemia locus is an evolutionarily con-
served locus that has allowed organisms with a liver and 
biliary system to perform this function, from fish to man 
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(9). Sitosterol may represent the most abundant of these 
dietary xenosterols, but this may have led to an error of 
scientific bias; all attention has focused on this sterol with-
out critical questioning of whether other more potent and 
toxic sterols (stigmasterol, avenosterol, fucosterol, and 
methyl-cholesterol to name a few) are major endocrine dis-
ruptors, harmful to megakaryocyte biology, or even alter 
macrophage and immune function (125). In sitosterol-
emia (and we propose that the term xenosterolemia be used 
to increase this awareness), feeding a diet rich in shellfish 
sterols led to accumulation of these exotic sterols within 
the body (5). Blocking entry of these xenosterols by the 
drug ezetimibe has been shown to ameliorate this condi-
tion (126, 127). Control subjects who have normal ABCG5/
ABCG8 function show trace plasma levels of these xenoste-
rols, indicating that we have a daily exposure of these xe-
nosterols to our tissues (5). Daily dietary intakes of these 
xenosterols are collectively greater than our daily dietary 
intake of cholesterol. ABCG5/G8 function as cholesterol 
regulators and in this role, because >99% of the mammalian 
body has cholesterol as its main sterol, cholesterol (and not 
xenosterol) trafficking remains as a key center piece. How-
ever, while the full spectrum of loss of sterolin function in 
humans may continue to evolve for this rare disease, the 
mammalian animal models have indicated that several bio-
logical steps can be disrupted by these xenosterols and that 
these processes are dependent on the continued presence 
of these xenosterols in their diets. We believe that it is time 
to contemplate mechanistic paths away from the cholesterol-
centric view of pathophysiology, especially where diets are 
a key component, and consider the role of xenosterols. If 
so, our scientific rigor in measuring and reporting the sterol 
spectrum may be a first step in defining the problem.
The authors are grateful to Dr. Jyh-Yeuan (Eric) Lee for his 
generosity in sharing the mapping of the missense mutations 
and the non-synonymous polymorphic changes in ABCG5 and 
ABCG8 (Fig. 1).
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